DRD1 and ovarian hyperstimulation syndrome: In recent years, both DRD1 and DRD2 agonists have been shown to prevent the development of vascular hyperpermeability in animal models of ALI 40, 42, ovarian hyperstimulation syndrome 48, and inflammatory bowel disease 49.